Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences Inc (ANIX) is a clinical-stage biotechnology company developing cancer immunotherapies and preventive cancer vaccines. The company's news flow centers on clinical trial progress, regulatory milestones, patent developments, and research collaborations advancing its oncology programs.
Investors tracking Anixa can expect news related to clinical trial data releases, particularly results from studies evaluating its chimeric endocrine receptor T-cell therapy for breast and ovarian cancers and its prophylactic breast cancer vaccine. The company announces investigational new drug application submissions, treatment of first patients in clinical studies, and completion of trial enrollment milestones as programs advance through development stages.
Patent-related announcements form another significant category of Anixa news, including notices of patent allowances from the U.S. Patent and Trademark Office, patent issuances in international markets, and expansions of intellectual property protection for both therapeutic technologies and the company's technology patent portfolio. These developments strengthen the company's commercial position and licensing revenue potential.
Research collaboration updates provide insight into partnerships with academic medical centers and cancer research institutions conducting sponsored studies. The company also announces participation in investor conferences and healthcare industry events where management presents corporate updates and interacts with the investment community.
Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering its breast cancer vaccine technology. The patent, exclusively licensed from Cleveland Clinic, provides composition-of-matter protection for their novel immunogenic approach in Canada.
The vaccine targets human α-lactalbumin, a protein expressed during lactation and in certain breast cancers. This technology addresses a significant market need, as breast cancer represents 25% of new cancer cases in Canadian women and 13% of female cancer deaths annually. The patent strengthens Anixa's international intellectual property portfolio and supports future regulatory and commercial efforts outside the U.S.
Anixa Biosciences (NASDAQ: ANIX) has been awarded U.S. Patent Number 12,370,244, extending protection for its breast cancer vaccine technology into the mid-2040s. The patent covers novel immunization methods using human α-lactalbumin protein, which is expressed during lactation and in certain breast cancers.
Developed in collaboration with Cleveland Clinic, this vaccine represents a pioneering approach to breast cancer prevention, targeting a significant unmet need. With 297,000 new cases of invasive breast cancer projected in 2025 and 43,000 expected deaths in the U.S., the technology addresses a potential multi-billion dollar market opportunity, particularly for women at risk of triple-negative breast cancer (TNBC).
Anixa Biosciences (NASDAQ: ANIX) announced the upcoming issuance of U.S. Patent Number 12,357,593 on July 15, 2025, strengthening its intellectual property portfolio for ovarian cancer vaccine technology. The patent covers methods of eliciting immune responses targeting anti-Müllerian hormone receptor, type II (AMHR2), a key target for ovarian cancer prevention and treatment.
The vaccine technology, developed in collaboration with Cleveland Clinic and the National Cancer Institute, focuses on preventing and treating ovarian cancer, particularly in high-risk populations with BRCA mutations or family history. The patent, issued to Cleveland Clinic with Anixa holding worldwide rights, includes methods for administering immunogenic compositions comprising nucleic acid encoding AMHR2 polypeptide.
FAQ
What is the current stock price of Anixa Biosciences (ANIX)?
What is the market cap of Anixa Biosciences (ANIX)?
